AWS Health Innovation Podcast

Heart failure affects over 60 million people worldwide, yet monitoring blood pressure inside the heart remains an invasive, complex procedure. In this episode of the AWS Health Innovation Podcast, Guy Spigelman, EMEA lead for Healthcare and Life Sciences Startups at AWS, speaks with Filip Peters, CEO of Acorai, about their groundbreaking non-invasive SAVE Sensor System that combines multiple sensing technologies to measure intracardiac pressures - potentially transforming how we manage heart failure.1. How did Filip transition from finance to healthcare technology?Drawing from his background in machine learning and financial technology, Filip identified an opportunity to apply advanced analytics to cardiac monitoring. His transition exemplifies how cross-industry expertise can drive healthcare innovation.2. What makes the SAVE Sensor System unique?The system integrates four distinct sensor types - seismic, acoustic, visual, and electrical - creating a comprehensive approach to non-invasive cardiac monitoring. This novel combination enables detailed measurement of intracardiac pressures without invasive procedures.3. How does Acorai's technology impact patient care?By enabling frequent, non-invasive pressure monitoring, healthcare providers can track heart failure progression more effectively. This capability supports earlier interventions and more precise treatment adjustments, potentially improving outcomes for millions of patients.4. What considerations went into the device design?Acorai prioritized portability and user experience, creating an intuitive interface that integrates seamlessly with existing hospital workflows. This practical approach addresses key adoption barriers in clinical settings.5. What milestones indicate Acorai's market potential?The company has expanded operations across six countries and received FDA Breakthrough Device Designation, demonstrating strong market validation and regulatory progress. These achievements reflect growing confidence in Acorai's innovative approach.Learn more about Acorai at https://acorai.com/Get in touch with AWS here to learn how we can help your organization accelerate healthcare innovation.Please take a moment and let us know what you think of the podcast, access our feedback survey here.

Nik Sharma, CEO of BioCorteX and clinician scientist, alongside CTO Muhannad Alomari, explores groundbreaking methods to influence drug efficacy through bacterial interactions. They discuss how emerging computational techniques can reshape personalized medicine and drug development. By applying engineering principles from aerospace to biotech, they highlight the significance of microbiome variations in medication responses. Their innovative Carbon Mirror platform showcases advanced modeling in oncology, offering insights for future biotech collaborations and the importance of unique approaches in drug discovery.

What if you could peer into the future of a clinical trial before enrolling a single patient? In this episode of the AWS Health Innovation Podcast, Alex Merwin, Head of Growth for Healthcare & Life Science Startups at AWS, sits down with Orr Inbar, Co-Founder & CEO of QuantHealth, to explore their groundbreaking platform that's revolutionizing drug development through clinical trial simulation. Their technology is transforming how pharmaceutical companies evaluate and advance potential therapies.1. How is QuantHealth reshaping pharmaceutical research?By leveraging an extensive database of 350 million patient records and sophisticated AI models, QuantHealth's platform achieves an impressive 86% accuracy in predicting trial outcomes. This capability directly addresses the industry's persistent challenges of rising costs and high failure rates.2. What fundamental industry challenges does QuantHealth address?The pharmaceutical industry struggles with average development costs of $3 billion and timelines exceeding a decade. Modern precision medicine requirements have added new layers of complexity to the drug development process, making traditional approaches increasingly challenging.3. How did QuantHealth evolve during the pandemic era?Born during COVID-19, QuantHealth developed an AI-driven solution that effectively bridges the critical gap between preclinical and clinical stages. Their platform now processes thousands of trials annually, demonstrating remarkable precision in predicting outcomes.4. What makes QuantHealth's technical approach unique?The platform combines biological knowledge graphs with deep learning models to create digital twins of both drugs and patients. This innovative approach spans more than 50 medical indications and multiple treatment modalities, enabling comprehensive trial simulation.5. What real-world impact has QuantHealth demonstrated?Through partnerships with major pharmaceutical companies, QuantHealth has helped increase trial success rates by 15% while simultaneously reducing development timelines. Their simulation technology has made previously unfeasible trials possible.Learn more about QuantHealth's innovative approach to clinical trial optimization at quanthealth.aiGet in touch with AWS here to learn how we can help your organization accelerate healthcare innovation.Please take a moment and let us know what you think of the podcast, access our feedback survey here.

From developing advanced technology for astronauts to revolutionizing medical device connectivity, every founders' innovation journey includes unexpected twists and turns. In this episode of the AWS Health Innovation Podcast, Yin He, Principal of Business Development for Healthcare & Life Sciences Startups at AWS, explores the transformative world of medical device cloud solutions with Alex Condon, COO and Co-founder of Galen Data. Their discussion reveals how Galen Data is helping medical device companies achieve FDA-compliant cloud connectivity in a fraction of the traditional time.1. How did the transition from NASA contracting to medical devices shape Galen Data's vision? Alex's experience in NASA contracting revealed striking parallels between spaceflight and medical device compliance requirements. This unique perspective helped shape Galen Data's approach to creating simplified, yet robust cloud infrastructure specifically for healthcare technology. 2. What key challenges do medical device companies face in today's market? Complex EHR integrations and stringent cybersecurity requirements create significant barriers to market entry. Galen Data addresses these challenges through standardized solutions and comprehensive expert support, enabling faster deployment while maintaining compliance. 3. How does Galen Data adapt its platform for different company sizes? The platform's configurable nature allows it to serve both startups and enterprise-level organizations effectively. Each implementation is tailored to address specific organizational needs while maintaining regulatory compliance and operational efficiency. 4. What factors contributed to Galen Data's successful acquisition? Detailed documentation practices and strategic relationship building proved crucial in the acquisition by Luxera Capital Partners. The company's organized approach to compliance and security documentation demonstrated significant value during the exit process. 5. What sets Galen Data apart in the medical device industry? Their commitment to genuine community engagement and customer success has fostered lasting partnerships beyond traditional business relationships. This approach has established Galen Data as a trusted partner in medical technology innovation. Learn more about Galen Data's innovative cloud platform for medical devices at galendata.comGet in touch with AWS here to learn how we can help your organization accelerate healthcare innovation.Please take a moment and let us know what you think of the podcast, access our feedback survey here.

Guy Spigelman, EMEA Healthcare and Life Sciences Startups lead at AWS, sits down with Michel van Harten MD, CEO of myTomorrows, to explore how artificial intelligence is revolutionizing clinical trial recruitment. myTomorrows is transforming the patient-trial matching process, reducing hours of manual screening to mere minutes through sophisticated AI automation - all while maintaining exceptional accuracy standards.1. How did a practicing physician become a digital health innovator?Driven by firsthand experiences with treatment access barriers, Michel van Harten MD, transitioned from clinical practice to leading myTomorrows, combining medical expertise with technological innovation to solve healthcare delivery challenges.2. What makes myTomorrows' platform unique in the clinical trial space?The platform leverages advanced AI to create seamless connections between patients, physicians, and clinical trials, achieving an impressive 98% accuracy rate while reducing physician screening time by over 90%.3. How does company culture contribute to patient impact?Monthly patient speakers and mission-focused initiatives keep their 110-person team deeply connected to their purpose. This values-driven approach helps attract top talent while maintaining sustainable growth.4. What is the global reach of myTomorrows' solution?Operating across 125 countries with 2,200+ physicians, the platform has facilitated treatment access for nearly 15,000 patients through expanded access programs and clinical trial matching.5. How has myTomorrows evolved from startup to scale-up?Through strategic pivots and technological advancement, myTomorrows has built a sustainable growth model, positioning themselves for growth equity funding and continued market expansion.Learn more about myTomorrows at https://mytomorrows.com/Get in touch with AWS here to learn how we can help your organization accelerate healthcare innovation.Please take a moment and let us know what you think of the podcast, access our feedback survey here.

Mika Newton, CEO of xCures, is changing the game in healthcare data accessibility using AI. She discusses how her company evolved from focusing on cancer solutions to a platform beneficial for all medical conditions. Mika explains xCures' unique approach in transforming fragmented records into structured, actionable insights while ensuring HIPAA compliance. The conversation highlights the pivotal role of their partnership with AWS for secure data processing and scalability, setting the stage for improved patient care and outcomes.

The convergence of artificial intelligence and biological engineering is ushering in a new era of drug design. On this episode of the AWS Health Innovation Podcast, Sanjit Misra speaks with Tharindi Hapuarachchi, VP of Platform Strategy & Operations at Generate:Biomedicines, about their groundbreaking work in generative biology. Through their innovative platform, they're revolutionizing how we design therapeutic proteins, bringing unprecedented speed and precision to drug development.1. How did Tharindi's unique background prepare her for pioneering work in biotech?Her journey from mathematics to bioengineering provides the perfect blend of analytical thinking and biological understanding needed for modern therapeutic development. This interdisciplinary expertise enables her to bridge the gap between computational design and practical applications in medicine.2. What makes Generate:Biomedicines' approach to protein design revolutionary?Their platform combines advanced machine learning with biological engineering in a novel "lab in the loop" system. This integration allows them to test millions of protein designs within weeks, dramatically accelerating the traditional drug discovery timeline.3. How does Generate:Biomedicines maintain seamless translation from design to application?A 330-person team operates both computational models and wet labs under one roof, creating an integrated ecosystem where AI-designed proteins can be rapidly tested and validated for therapeutic use.4. What real-world success demonstrates the platform's capabilities?Their COVID antibody development program showcases the platform's power, completing in just 17 months. The ability to simultaneously optimize multiple properties represents a significant advancement over traditional pharmaceutical development methods.5. How does Generate:Biomedicines' infrastructure support rapid innovation?Their system combines proprietary protein databases with 24/7 automated laboratories, enabling continuous learning and iteration in the protein design process. This infrastructure creates a powerful feedback loop that enhances the platform's capabilities over time.6. What potential impact could this technology have on healthcare accessibility?The platform aims to reduce development costs while accelerating therapeutic creation, potentially enabling more personalized treatments for underserved populations and improving access to breakthrough medicines.Learn more about Generate:Biomedicines at generatebiomedicines.comGet in touch with AWS here to learn how we can help your organization accelerate healthcare innovation.Please take a moment and let us know what you think of the podcast, access our feedback survey here.

In a groundbreaking advancement for health monitoring, a device the size of a band-aid is transforming how we prevent medical emergencies. On this episode of the AWS Health Innovation Podcast, Yin He, Principal of Business Development for Healthcare & Life Sciences Startups, explores the future of patient care with Dr. Jim Mault, CEO and Founder of BioIntelliSense. Their conversation reveals how continuous vital sign monitoring is revolutionizing the century-old practice of patient observation.How is BioIntelliSense transforming traditional vital sign monitoring?The BioButton device captures an unprecedented 1,440 measurements daily, enabling continuous, AI-powered health monitoring. This medical-grade wearable represents a paradigm shift from periodic to constant patient observation.What makes the healthcare command center system unique?Healthcare providers can monitor up to 300 patients simultaneously through an innovative exception management system. The platform uses color-coding to transform complex data streams into actionable insights, similar to modern aviation control systems.How does continuous monitoring impact patient recovery?The system has demonstrated an impressive 80% reduction in 30-day readmissions by bridging the critical monitoring gap between hospital discharge and home recovery, providing enhanced security for both patients and their families.What role does cognitive computing play in healthcare data management?While healthcare facilities generate vast amounts of data, BioIntelliSense's cognitive computing approach processes this previously unused information into clear, actionable insights, following the successful evolution model of aviation safety systems.How does BioIntelliSense ensure successful clinical adoption?The company employs a structured three-phase implementation process, focusing on education and transformation. Healthcare facilities using the BioButton system report significant improvements in patient outcomes and reductions in unplanned transfers.What makes BioIntelliSense's approach sustainable?The company combines a subscription-based model with reusable devices to create both environmental and economic sustainability, while maintaining FDA compliance and clinical efficacy.Learn more about BioIntelliSense at www.biointellisense.comGet in touch with AWS here to learn how we can help your organization accelerate healthcare innovation.Please take a moment and let us know what you think of the podcast, access our feedback survey here.

The global food system faces an unprecedented challenge: producing 50% more food by 2050 using today's available land. On the AWS Health Innovation Podcast, Yin He, Principal of Business Development for Healthcare & Life Sciences Startups, explores this critical issue with Ponsi Trivisvavet, CEO of Inari Agriculture. Learn how this innovative company is revolutionizing agriculture through AI-powered predictive design and advanced multiplex gene editing to create more efficient, sustainable crops.1. How is Inari reimagining seed development for a sustainable future?By combining AI-powered predictive design with CRISPR technology, Inari creates resilient, high-yield crops that maximize resource efficiency. Their breakthrough approach directly addresses global food security while minimizing environmental impact.2. What inspired the transition from electrical engineering to agricultural innovation?Ponsi Trivisvavet's background in electrical engineering evolved into a passion for agricultural transformation after witnessing technology's direct impact on farming communities. This experience fundamentally shapes Inari's mission to revolutionize crop development.3. How does Inari overcome traditional seed development limitations?While conventional breeding faces significant constraints in annual yield improvements, Inari's advanced gene editing platform accelerates natural breeding processes, radically reducing development timelines.4. What makes Inari's technology approach unique?The company employs a dual-technology strategy, leveraging both artificial intelligence and multiplex gene editing. Their predictive design system analyzes complex crop genomes to identify optimal genetic modifications for improved crop performance.5. How does Inari's business model support agricultural transformation?Through strategic partnerships and royalty arrangements with existing seed companies, Inari focuses on corn, soybeans, and wheat - crops that represent 70% of global markets - to maximize their impact on food security.6. What drives Inari's rapid growth and innovation?A culture of continuous innovation, including unique benefits and dedicated innovation leadership, has fueled Inari's expansion from 30 to over 300 employees. Their "What if?" mindset consistently challenges traditional agricultural limitations.Learn more about Inari Agriculture's innovative approach to securing our food future at inari.comGet in touch with AWS here to learn how we can help your organization accelerate healthcare innovation.Please take a moment and let us know what you think of the podcast, access our feedback survey here.

Healthcare professionals access over 5 million medical references annually through Eolas Medical's platform. In this episode of the AWS Health Innovation Podcast, Alex Merwin, Head of Growth for Healthcare & Life Science Startups at AWS, sits down with Rob Brisk, Former Chief Scientific Officer of Eolas Medical. Eolas provides a digital platform that organizes medical information, helping healthcare providers quickly find answers to clinical questions at the point of care. This conversation explores the intersection of technology and healthcare, offering valuable insights into the future of medical knowledge management. How is Eolas Medical approaching AI integration in healthcare? Eolas Medical takes a cautious approach to AI integration, prioritizing safety and regulatory compliance. They balance the potential of AI with the need to maintain high standards of patient care and ethical considerations, reflecting the broader challenges in the healthcare industry. What inspired Rob Brisk's transition from cardiology to healthcare technology? Rob Brisk's journey from practicing cardiologist to tech innovator exemplifies the growing intersection of medicine and technology. His experience highlights the potential for clinicians to drive meaningful change in healthcare through digital solutions, bridging the gap between medical expertise and technological innovation. How does Eolas Medical's platform address critical needs in healthcare? The platform provides rapid access to up-to-date medical information, aligning with the industry's push towards evidence-based practice. By streamlining access to medical knowledge, Eolas supports improved efficiency in clinical decision-making and helps healthcare professionals stay current with the latest medical information. What challenges does Eolas face in building trust for their clinical AI systems? The development of Eolas Medical's RAG system highlights the complexities of introducing AI into clinical settings. Key challenges include gaining clinician acceptance, defining the role of AI in decision support, and maintaining the essential human element in healthcare while leveraging technological advancements. How does Eolas Medical's unique team composition contribute to healthcare innovation? With 70% of their engineers having medical backgrounds, Eolas Medical showcases a powerful model for healthcare innovation. This physician-engineer approach bridges the gap between clinical needs and technological solutions, potentially accelerating the development of effective digital health tools and ensuring that innovations are grounded in real-world medical practice. To learn more about Eolas Medical and their innovative platform for healthcare professionals, visit their website at https://www.eolasmedical.com/. Get in touch with AWS here to learn how we can help your organization accelerate healthcare innovation. Please take a moment and let us know what you think of the podcast, access our feedback survey here.